GlobalData, April 2011, Pages: 81
valuable insights on the pipeline products within the global HIV/AIDS therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary
Datamonitor, Dec 2009, Pages: 160
of therapeutic vaccines against HIV
Disease background - HIV prevalence is highest in the developing world
HAART has transformed HIV into a chronic disease, with many treatmentoptions available
Viral
Datamonitor, March 2008, Pages: 123
the market 40
Despite Synagis success there are relatively few MAbs in late-stage development for RSV 42
Motavizumab 43
HIV 44
Disease background 44
Current treatmentoptions 45
HIV etiology and drug targets 45
GlobalData, June 2011, Pages: 61
HIV incidence and weak pipeline activity. The advent of HAART (Highly Active Antiretroviral Treatment) therapy coupled with antiangiogenics has enabled the effective management of ARKS and prolonged
Datamonitor, Aug 2010, Pages: 142
(HIV). High disease burdens, low diagnosis and treatment rates, and a lack of marketed interventions for the prevention of most STDs highlight the clinical and commercial potential in this area.
Scope
MP Advisors, Jan 2011, Pages: 391
/ Inflammation diseases have seen the best outcome –
both in targeting unmet needs and better patient friendly treatmentoptions.
Oral drug (INCB28050, R788, RDEA594, Gilenya) options are likely to make way
GlobalData, Sep 2011, Pages: 93
to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cytomegalovirus (CMV) Infections sector
GlobalData, March 2011, Pages: 51
the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CMV Retinitis sector.
This report is built using data
Datamonitor, Sep 2008, Pages: 108
, antibacterial and transplant portfolios are aimed at critical care physicians 28
Figure 15: Shire is committed to developing a range of treatments for ADHD patients 31
Figure 16: GlaxoSmithKlines HIV portfolio
GlobalData, July 2011, Pages: 37
&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine
PharmaVision, July 2009, Pages: 225
This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines. It provides opinions & market projections to:
- assess the commercial potential
